Abstract. The silencing of tumor suppressor genes (TSGs) by aberrant hypermethylation occurs frequently in human cancer. Recently the RUNX3 gene was identified as a TSG inactivated by hypermethylation. We examined RUNX3 expression by reverse transcription-PCR and the methylation status of this gene by methylation specific-PCR in 43 lung cancer cell lines and 120 primary non-small cell lung cancer (NSCLC) tumor samples. RUNX3 expression was absent in 10 (50%) of 20 small cell lung cancer (SCLC) cell lines, 8 (50%) of 16 adenocarcinoma (AdC) cell lines, and 1 (33.3%) of 3 squamous cell carcinoma (SqC) cell lines. The frequency of RUNX3 methylation was significantly higher in AdC (7/16, 43.8%) than SCLC cell lines (1/20, 5%; p=0.032). RUNX3 expression was restored by treatment with 5-aza-2'-deoxycytidine and/or trichostatin-A in AdC cell lines. These results indicated that RUNX3 expression was regulated by aberrant hypermethylation in AdC cell lines. RUNX3 methylation was detected in 30 (25%) of 120 primary NSCLC tumors. RUNX3 methylation was significantly more frequent in non-smokers (16/43, 37.2%) than smokers (12/71, 16.9%; p=0.014), and in patients with AdC (26/72, 36.1%) than in patients with SqC (3/45, 6.7%; p<0.001). These results indicated that silencing of the RUNX3 gene plays an important role in the pathogenesis of lung cancer, and aberrant methylation is an important mechanism of inactivation of the RUNX3 gene in lung AdC.
Introduction
Lung cancer is the leading cause of cancer-related deaths in the world (1) . Human lung cancer is classified into two major histological subtypes, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC). The two types differ in clinical, therapeutic, and biological features, as well as genetic alterations such as RB and p16 (2, 3) .
The runt-domain-related (RUNX) proteins are transcription factors which target the TGF-ß signaling pathway. RUNX proteins have been shown to interact with downstream SMAD protein in mediating the growth-suppressive effects of TGF-ß (4). In mammals, there are three families of runt-related genes,
RUNX1 (PEBP2·B/CBFA2/AML1), RUNX2 (PEBP2·A/ CBFA1/AML3), and RUNX3 (PEBP2·C/CBFA3/AML2).
All three play important roles in both normal developmental processes and carcinogenesis (5, 6) . The RUNX3 gene is a putative tumor suppressor gene located at 1p36, a region that frequently exhibits loss of heterozygosity events in several cancer types including lung cancer (7) . Loss of RUNX3 expression leads to the abnormal proliferation of gastric epithelial cells, a lack of responsiveness to apoptosis, and a growth-inhibitory effect induced by TGF-ß (8) . Though structural mutations and deletions of RUNX3 are rare, a reduction of RUNX3 expression frequently occur in cancers including gastric and colorectal cancers (8, 9) . However, the expression of RUNX3 in lung cancer has not been fully examined.
Aberrant hypermethylation of CpG islands is an important mechanism that results in a loss of gene expression (10) . A reduction in the expression of the RUNX3 gene caused by aberrant methylation has been frequently found (8, 9) . Aberrant methylation was also found in lung cancers (11, 12) . However, no study has analyzed the correlation between the expression and the methylation status of the RUNX3 gene in lung cancer, especially subtypes of lung cancer such as SCLC, AdC and SqC.
In the present study, we examined RUNX3 expression and methylation status in 43 lung cancer cell lines (20 SCLC and 23 NSCLC cell lines), and analyzed the methylation status of RUNX3 in 120 primary NSCLC tumor samples. Furthermore, we analyzed the association between RUNX3 methylation and clinicopathological characteristics in patients with NSCLC. A total of 43 lung cancer cell lines  were studied including 20 SCLCs (NCI-H187, -H209, -H378,  -H524, -H526, -H740, -H865, -H1045, -H1092, -H1184, -H1238, -H1339, -H1607, -H1618, -H1963, -H2107, -H2141,  -H2171, -H2227, and HCC33) and 23 NSCLCs (NCI-H322,  -H460, -H520, -H661, -H838, -H1264, -H1299, -H1395,  -H1437, -H1648, -H1792, -H1819, -H2009, -H2087, -H2106,  -H2122, HCC15, HCC44, HCC78, HCC95, HCC193,  HCC515 , and A549) established previously (13) . The cells were grown in RPMI-1640 medium (Sigma) supplemented with 10% fetal bovine serum and incubated in 5% CO 2 at 37˚C.
Materials and methods

Cell lines and cell culture.
Tissue specimens. Primary lung tumors were obtained from 120 patients with NSCLC. All patients underwent surgery at the Gunma University Hospital or National Nishigunma Hospital, Gunma, between August 1991 and March 2001. The tumors were histologically classified as AdCs (n=72), SqCs (n=45), large cell carcinomas (LCCs, n=2), Adenosquamous carcinoma (n=1) according to the Histological Typing of Lung Tumors of the World Health Organization (14) . The tumors were frozen and stored at -80˚C until the extraction of DNA.
Extraction of DNA and RNA. Genomic DNA was prepared as previously described (15) or else with a QIAamp DNA mini kit (Qiagen, Tokyo, Japan) or DNeasy kit (Qiagen). RNA was prepared using an RNeasy kit (Qiagen). In all cases, the manufacturer's instructions were followed.
Reverse transcription (RT)-PCR. RUNX3 mRNA expression was measured by RT-PCR. The RNA (3 μg) was reverse transcribed in a volume of 20 μl using SuperScript II (Invitrogen) according to the manufacturer's instructions. The cDNA (1 μl) was used for the analysis of RUNX3 with specific primer sequences. The RUNX3 primers were 5'-GAGTTTCACCCTG ACCATCACTGTG-3' (sense) and 5'-GCCCATCACTGGT CTTGAAGGTTGT-3' (antisense), which yielded 870-base pair (bp) PCR products (8) . The gene for Glyceraldehyde 3' phosphate dehydrogenase (GAPDH), a house keeping gene, was used to check the integrity of the RNA in all samples (16) . The PCR amplification consisted of denaturation at 95˚C for 15 min, 35 cycles of denaturation at 95˚C for 20 sec, annealing at 55˚C for 60 sec, and extension at 72˚C for 90 sec, and a final extension at 72˚C for 10 min. The PCR products were separated in 2% agarose gels with ethidium bromide and visualized under UV illumination.
Methylation-specific PCR (MSP).
The methylation status of RUNX3 was analyzed by MSP using bisulfite-modified genomic DNA. The modification of DNA with bisulfite was performed as described previously (17) . Briefly, 1 μg of genomic DNA was denatured with 0.2 M NaOH. Then, 10 mM hydroquinone (Sigma) and 3 M sodium-bisulfite (Sigma) were added and the solution was incubated at 55˚C for 16 h. Treatment of genomic DNA with sodium bisulfite converts Table I . Incidence of loss of RUNX3 mRNA expression in lung cancer cell lines. 
unmethylated (but not methylated) cytosines to uracil, which is then converted to thymidine during subsequent PCR to give sequence differences between methylated and unmethylated DNA. The modified DNA was used as a template for MSP with primers specific for either the modified methylated or the modified unmethylated RUNX3 promoter sequences. Two distinct promoters, P1 and P2, regulate RUNX3 transcription. The major RUNX3 mRNA is transcribed from P2. The genomic region surrounding the P2 promoter contributes to a large CpG island (18) . P2 possesses the hall mark characteristics of a GCrich promoter. Thus, in theory it is rational that transcription from P2 should be regulated by DNA methylation. We examined the region using two sets of primers specific for MSP, described previously (8) . The primer sequences for the methylated RUNX3 gene were 5'-TTACGAGGGGCGGTCG TACGCGGG-3' (sense) and 5'-AAAACGACCGACGCGA ACGCCTCC-3' (antisense), and for the unmethylated allele were 5'-TTATGAGGGGTGGTTGTATGTGGG-3' (sense) and 5'-AAAACAACCAACACAAACACCTCC-3' (antisense). Each primer set generated a 220-bp product. PCR was performed for a total of 35 cycles at an annealing temperature of 63˚C for the methylated primers and 57˚C for the unmethylated primers using HotStar Taq DNA Polymerase (Qiagen). The PCR products were separated in 2% agarose gels with ethidium bromide and visualized under UV illumination.
5-aza-2'-deoxycytidine (5-aza-dC) and trichostatin-A (TSA)
treatment. Cells were incubated with medium containing 10 μM 5-aza-dC (Sigma), or 0.5 μM TSA (Wako, Tokyo) for 48 h. In the synergistic study, the cells were cultured with 10 μM 5-aza-dC for 48 h and then with 0.5 μM TSA for another 24 h. We isolated total RNA with an RNeasy mini kit (Qiagen), and performed RT-PCR.
Statistical analysis.
Fisher's exact test was used to examine the association of two categorical variables. A p-value of <0.05 was considered to be statistically significant. Statistical analysis was performed using StatView J-4.5 for Macintosh. Both methylated and unmethylated alleles were found in one (NCI-H1184) of the SCLC cell lines and one (NCI-H838) of the AdC cell lines (Fig. 1b and Table II ). Then we analyzed the correlation between the expression and the methylation status of the RUNX3 gene. Unmethylated alleles were detected in all RUNX3-expressing SCLC and NSCLC cell lines including NCI-H1184 and -H838. Methylated alleles were detected in none (0%) of 10 SCLC, 7 (70%) of 10 NSCLC, 6 (75%) of 8 AdC, none (0%) of 1 SqC, and 1 (100%) of 1 LCC cell lines which were negative for the RUNX3 expression (Table III) .
Results
RUNX3 expression and methylation status in lung cancer
Restoration of RUNX3 expression by 5-aza-dC and TSA.
To assess whether the loss of RUNX3 expression in lung cancer was a result of aberrant methylation and/or histone Table III . Correlation between expression and methylation of RUNX3 in lung cancer cell lines. 
-----------------------------------------------------------------------------------------------------
RUNX3 RUNX3 promoter genotype ------------------------ Total expression Total M a alleles U a
alleles -----------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
a M, methylated; U, unmethylated.
b Both M allele and UM allele were exhibited. Table II . Presence of methylated and unmethylated RUNX3 alleles in lung cancer cell lines.
-----------------------------------------------------------------------------------------------------
- +  +  1  1  1  0  0  +  -0  7  6  0  1  -+  19  15  9  3  3  --0  0  0  0  0  Total  20  23  16  3  4 ----------------------------------------------------------------------------------------------------- deacetylation, we examined the effect of the demethylating agent 5-aza-dC and/or histone deacetylase inhibitor TSA on 4 cell lines without RUNX3 expression. The results are shown in Fig. 2 . The expression was restored by the treatment with 5-aza-dC and/ or TSA in two cell lines (NCI-H1437 and -H1648) in which aberrant methylation was detected by MSP. On the other hand, the expression was not restored by the treatment with 5-aza-dC or TSA in two cell lines (NCI-H520 and -H2009) in which no aberrant methylation was detected by MSP. Although the expression was not restored by treatment with the combination of 5-aza-dC and TSA in NCI-H520, it was restored by this treatment in NCI-H2009.
----------------------------------------------------------------------------------------------------
RUNX3 promoter genotype -------------------------- M a alleles U a alleles SCLC NSCLC AdC SqC LCC -
Correlation between RUNX3 methylation and clinicopathological features in primary NSCLCs. One hundred and twenty primary NSCLC tumor samples were examined for RUNX3 methylation by MSP. Representative examples are illustrated in Fig. 3 . RUNX3 methylation was detected in 30 (25%) of the 120 tumors. All tumor samples had unmethylated alleles. We then analyzed the relationship between the methylation of RUNX3 and the clinicopathological characteristics of these patients. The results are summarized in Table IV Table IV . Correlation of RUNX3 methylation with clinicopathological characteristics of patients with non-small cell lung cancer. 
Discussion
We first examined the expression and methylation status of RUNX3 in 43 lung cancer cell lines by RT-PCR and MSP. The expression was frequently absent in lung cancer cell lines, and the frequency of loss of expression was similar among the histological subtypes. On the other hand, though the aberrant methylation of RUNX3 was frequently detected in AdC cell lines, it was rare in SCLC and SqC cell lines. Furthermore, the expression was restored by treatment with 5-aza-dC or 5-azadC plus TSA in the AdC cell lines NCI-H1437, -H1648, and -H2009, though the expression was not restored by this treatment in the SqC cell line NCI-H520. These results indicated that the expression was regulated by aberrant hypermethylation in AdC cell lines, while it was not regulated by hypermethylation in the SCLC or SqC cell lines. It has been reported that the RUNX3 gene was inactivated by aberrant methylation in gastric, colorectal, bile duct, and pancreatic cancers (8, 9, 19, 20) the predominant form of which is AdC. These previous results and the present study suggested that loss of RUNX3 expression due to aberrant methylation is specific to the subtype of AdC in several human cancer types. One AdC cell line (NCI-H838) expressed RUNX3 though it had a methylated allele ( Fig. 1 and Table III) . However, since unmethylated alleles were also present in this cell line, RUNX3 expression was detected. We next analyzed the methylation status of the RUNX3 gene in 120 primary NSCLC tumors, and found the frequency of RUNX3 methylation to be 25%. The frequency was slightly higher compared to previous findings (21, 22) . The discrepancy in the results might be due to the difference in the population. AdC was the predominant histological subtype in the present study. We then analyzed the relationship between methylation of the RUNX3 gene and the clinicopathological characteristics of these patients. One interesting aspect of the present study is that RUNX3 methylation was frequently observed in non-smokers. Genetic and epigenetic changes in lung cancer have been almost always more frequent in smokers than non-smokers, such as mutations of p53 and KRAS, and aberrant hypermethylation of p16 and APC (2, 3, 23, 24) . Although it is unclear why RUNX3 methylation was predominantly detected in patients with no history of smoking, it is reasonable to assume that the methylation is caused by carcinogens other than those contained in tobacco smoke. Cheng et al investigated infections with the human papilloma virus as a cause of lung cancer in female nonsmokers (25) . Sakura et al reported the aberrant hypermethylation of multiple genes in gastric cancer associated with infections with the Epstein-Barr virus (26) . Although the Epstein-Barr virus is rarely affected with lung carcinogenesis (27) , RUNX3 methylation might be induced by infections with some viruses. Recently, it was reported that mutations in the tyrosine kinase domain of the EGFR gene occurred in patients with no history of smoking (28, 29) . This is similar to the results of RUNX3 methylation status in the present study. However, the mechanism of these molecular abnormalities and the association of RUNX3 methylation with EGFR mutation is not known. Further analyses will be needed to clarify the carcinogenesis and progression of lung cancer in non-smokers. We also found that RUNX3 methylation was preferentially observed in AdC rather than SqC in primary NSCLCs as the results of an analysis of lung cancer cell lines. Molecular differences between AdC and SqC have been described in previous studies, including allelic loss at 3p, mutations of p53 and RASSF1A methylation (12, 30, 31) . Yanagawa et al reported that methylation of RUNX3 and APC occurred more frequently in AdC than SqC (21) . The result of the present study was consistent with this previous study. Therefore, these results including the analysis of the cell lines suggested that methylational inactivation of the RUNX3 gene plays an important role in the pathogenesis of lung AdC.
In conclusion, loss of RUNX3 expression was frequently detected in all histological subtypes of lung cancer cell lines. The silencing mechanism was the aberrant hypermethylation in AdC cell lines, but not in SCLC cell lines. Methylation of RUNX3 also frequently occurred in primary AdC, especially among patients who were non-smokers. These results indicated that silencing of the RUNX3 gene plays an important role in the pathogenesis of lung cancer, and aberrant methylation is an important mechanism of inactivation of the RUNX3 gene in lung AdC.
